Damora Therapeutics, Inc.
DMRA · XNASCIK 1800315fmd_1DHVJPWZZKNHSK2C8T385MSKQ6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 30 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Net interest income | – | – | 0 | 1 | 2 | 1 | 1 |
| Research and development | 20 | 25 | 38 | 48 | 24 | 6 | 27 |
| Total operating expenses | 39 | 34 | 52 | 61 | 40 | 22 | 211 |
| Operating income | 39 | (34) | (52) | (61) | (40) | (22) | (211) |
| Other non-operating income (expense) | 2 | (1) | 0 | (0) | 2 | 1 | 1 |
| Income before taxes | (37) | (35) | (52) | (62) | (38) | (21) | (210) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (37) | (35) | (52) | (62) | (38) | (21) | (210) |
| Net income | (37) | (35) | (52) | (62) | (38) | (21) | (210) |
| Net income to common shareholders | (42) | (35) | – | – | – | – | – |